High variability in LLMs’ analogical reasoning
2025 De Varda, A; Saponaro, C; Marelli, M
The reasons why maximum diversification is better than minimum risk, including in terms of risk
2025 Torrente, M; Uberti, P
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
2025 Olawaiye, A; Gladieff, L; O'Malley, D; Kim, J; Garbaos, G; Salutari, V; Gilbert, L; Mileshkin, L; Devaux, A; Hopp, E; Lee, Y; Oaknin, A; Scaranti, M; Kim, B; Colombo, N; Mccollum, M; Diakos, C; Clamp, A; Leiser, A; Balazs, B; Monk, B; Scandurra, G; Mcclung, E; Kaczmarek, E; Slomovitz, B; De La Cueva, H; De Carvalho Calabrich, A; Cassani, C; You, B; Van Gorp, T; Churruca, C; Caruso, G; Nicum, S; Bagameri, A; Artioli, G; Bodnar, L; Kang, S; Vergote, I; Kesner-Hays, A; Pashova, H; Pai, S; Tudor, I; Jubb, A; Lorusso, D
DNA methylation signatures to predict the cervicovaginal microbiome status
2020 Nene, N; Barrett, J; Jones, A; Evans, I; Reisel, D; Timms, J; Paprotka, T; Leimbach, A; Franchi, D; Colombo, N; Bjorge, L; Zikan, M; Cibula, D; Widschwendter, M
Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): Overall Survival Results From a Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial
2025 Lorusso, D; Xiang, Y; Hasegawa, K; Scambia, G; Leiva, M; Ramos-Elias, P; Acevedo, A; Cvek, J; Randall, L; De Santana Gomes, A; Mejia, F; Helpman, L; Akilli, H; Lee, J; Saevets, V; Zagouri, F; Gilbert, L; Sehouli, J; Tharavichitkul, E; Lindemann, K; Colombo, N; Chang, C; Bednarikova, M; Zhu, H; Oaknin, A; Christiaens, M; Petru, E; Usami, E; Liu, P; Yamada, K; Toker, S; Keefe, S; Pignata, S; Duska, L
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
2025 Banerjee, S; Van Nieuwenhuysen, E; Aghajanian, C; D'Hondt, V; Monk, B; Clamp, A; Prendergast, E; Oaknin, A; Ring, K; Colombo, N; Holloway, R; Rodrigues, M; Chon, H; Gourley, C; Santin, A; Thaker, P; Gennigens, C; Newman, G; Salinas, E; Youssoufian, H; Moore, K; Lustgarten, S; O'Malley, D; Van Gorp, T; Grisham, R
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025
2025 Concin, N; Matias-Guiu, X; Cibula, D; Colombo, N; Creutzberg, C; Ledermann, J; Mirza, M; Vergote, I; Abu-Rustum, N; Bosse, T; Chargari, C; Espenel, S; Fagotti, A; Fotopoulou, C; Gatius, S; Gonzalez-Martin, A; Lax, S; Levy, B; Lorusso, D; Macchia, G; Marth, C; Morice, P; Oaknin, A; Raspollini, M; Schwameis, R; Sehouli, J; Sturdza, A; Taylor, A; Westermann, A; Wimberger, P; Planchamp, F; Nout, R
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial
2025 Ledermann, J; Oza, A; Lorusso, D; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; Weberpals, J; Clamp, A; Scambia, G; Leary, A; Holloway, R; Gancedo, M; Fong, P; Goh, J; O'Malley, D; Armstrong, D; Banerjee, S; Garcia-Donas, J; Swisher, E; Lebreton, C; Konecny, G; Mcneish, I; Scott, C; Maloney, L; Goble, S; Lin, K; Coleman, R
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial
2025 Harano, K; Fossati, R; Pardo, B; Galli, F; Hudson, E; Antill, Y; Lee, C; Rabaglio, M; Heitz, F; Kolovetsiou-Kreiner, V; Lai, C; Biagioli, E; Manso, L; Nishio, S; Allan, K; Lee, Y; Uggeri, S; Redondo, A; Nakagawa, S; Au, E; Lombard, J; Gadducci, A; Takehara, K; Baldini, E; Palaia, I; Casanova, C; Ardizzoia, A; Bologna, A; Barretina-Ginesta, M; Colombo, N
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
2025 Kim, Y; Nishio, S; Kim, S; Hasegawa, K; Dubot, C; Valeria Cáceres, M; Tewari, K; Lorusso, D; Lee, J; Liou, W; Li, K; Tekin, C; Colombo, N; Monk, B
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer
2025 Randall, L; Xiang, Y; Matsumoto, T; Giannarelli, D; Milla, D; Lopez, K; Acevedo, A; Vizkeleti, J; Salani, R; Nogueira-Rodrigues, A; Mejia, F; Korach, J; Akilli, H; Lee, J; Saevets, V; Samouelian, V; Sehouli, J; Tharavichikul, E; Sukhin, V; Colombo, N; Chang, C; Cueva, J; Lalondrelle, S; Petru, E; Szamreta, E; Nguyen, A; Yamada, K; Li, K; Pignata, S; Lorusso, D
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
2023 Matulonis, U; Lorusso, D; Oaknin, A; Pignata, S; Dean, A; Denys, H; Colombo, N; Van Gorp, T; Konner, J; Marin, M; Harter, P; Murphy, C; Wang, J; Noble, E; Esteves, B; Method, M; Coleman, R
Dose-dense neoadjuvant chemotherapy before radical surgery in cervical cancer: a retrospective cohort study and systematic literature review
2024 Caruso, G; Bruni, S; Lapresa, M; De Vitis, L; Parma, G; Minicucci, V; Betella, I; Schivardi, G; Peccatori, F; Lazzari, R; Cliby, W; Aletti, G; Zanagnolo, V; Maggioni, A; Colombo, N; Multinu, F
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
2021 Concin, N; Creutzberg, C; Vergote, I; Cibula, D; Mirza, M; Marnitz, S; Ledermann, J; Bosse, T; Chargari, C; Fagotti, A; Fotopoulou, C; Gonzalez-Martin, A; Lax, S; Lorusso, D; Marth, C; Morice, P; Nout, R; O'Donnell, D; Querleu, D; Raspollini, M; Sehouli, J; Sturdza, A; Taylor, A; Westermann, A; Wimberger, P; Colombo, N; Planchamp, F; Matias-Guiu, X
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
2021 Concin, N; Matias-Guiu, X; Vergote, I; Cibula, D; Mirza, M; Marnitz, S; Ledermann, J; Bosse, T; Chargari, C; Fagotti, A; Fotopoulou, C; Martin, A; Lax, S; Lorusso, D; Marth, C; Morice, P; Nout, R; O'Donnell, D; Querleu, D; Raspollini, M; Sehouli, J; Sturdza, A; Taylor, A; Westermann, A; Wimberger, P; Colombo, N; Planchamp, F; Creutzberg, C
Immune checkpoint inhibitors alone or in combination for endometrial mismatch repair-deficient/MSI-high population
2024 Canario, R; Colombo, N; Joly, F
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
2023 Pujade-Lauraine, E; Selle, F; Scambia, G; Asselain, B; Marme, F; Lindemann, K; Colombo, N; Madry, R; Glasspool, R; Vergote, I; Korach, J; Lheureux, S; Dubot, C; Oaknin, A; Zamagni, C; Heitz, F; Gladieff, L; Rubio-Perez, M; Scollo, P; Blakeley, C; Shaw, B; Ray-Coquard, I; Redondo, A
Quantitative Proteomics and Phosphoproteomics Analysis of Patient-Derived Ovarian Cancer Stem Cells
2025 Franciosa, G; Nieddu, V; Battistini, C; Caffarini, M; Lupia, M; Colombo, N; Fusco, N; Olsen, J; Cavallaro, U
Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study
2025 Valenza, C; Mongillo, M; Visconti, M; Katrini, J; Trapani, D; Boldrini, L; Guidi, L; Farfalla, A; Malengo, D; Caruso, G; Derio, S; Lapresa, M; Parma, G; Biagioli, E; Omodeo Salé, E; Curigliano, G; Colombo, N
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
2025 Oza, A; Lisyanskaya, A; Fedenko, A; De Melo, A; Shparyk, Y; Rakhmatullina, I; Bondarenko, I; Colombo, N; Svintsitskiy, V; Biela, L; Nechaeva, M; Lorusso, D; Scambia, G; Cibula, D; Poka, R; Oaknin, A; Safra, T; Mackowiak-Matejczyk, B; Ma, L; Thomas, D; Lin, K; Mclachlan, K; Goble, S; Kristeleit, R
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Keyword
- Humans5349
- Female2958
- Male2610
- Middle Aged1877
- Adult1780
- Aged1484
- Italy1171
- COVID-191143
- Animals1031
- Nuclear and High Energy Physics742
Rivista
- JOURNAL OF HIGH ENERGY PHYSICS1321
- PHYSICAL REVIEW LETTERS906
- JOURNAL OF HYPERTENSION787
- PHYSICS LETTERS. SECTION B699
- PHYSICAL REVIEW D557
- THE EUROPEAN PHYSICAL JOURNAL. C, PARTICLES AND FIELDS522
- SCIENTIFIC REPORTS498
- MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY485
- PLOS ONE455
- ASTRONOMY & ASTROPHYSICS448
Editore
- Springer2364
- Elsevier B.V.2190
- Elsevier2164
- Oxford University Press2152
- Elsevier Ltd2129
- American Physical Society1996
- MDPI1862
- Elsevier BV1711
- Elsevier Inc.1278
- Lippincott Williams and Wilkins1228
Lingua
- eng71040
- ita15151
- fre371
- spa233
- por85
- ger53
- ara23
- rus14
- arc8
- chi8
Settore disciplinare
- MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE62
- M-PED/01 - PEDAGOGIA GENERALE E SOCIALE45
- M-PSI/08 - PSICOLOGIA CLINICA39
- INF/01 - INFORMATICA34
- FIS/05 - ASTRONOMIA E ASTROFISICA33
- GEO/08 - GEOCHIMICA E VULCANOLOGIA27
- ING-INF/05 - SISTEMI DI ELABORAZIONE DELLE INFORMAZIONI26
- IUS/08 - DIRITTO COSTITUZIONALE26
- CHIM/03 - CHIMICA GENERALE ED INORGANICA25
- IUS/01 - DIRITTO PRIVATO25
Tipologia
- 01 - Articolo su rivista86718
- 99 - Altro3
- 03 - Contributo in libro2
- 02 - Intervento a convegno1
Accesso al fulltext
- no fulltext48977
- open21709
- reserved14381
- partially open1580
- embargoed63
- mixed13
Progetto
- -1002
- DIP-ECC-DISAT-2018242
- DIP-ECC-MATER-2018152
- MUSA41
- DIP-ECC-FORMAZIONE-2327
- DIP-ECC-PSICOLOGIA-202321
- SWAB20
- UNIMIB-ARIA Toolkit20
- UNICORN19
- ICSC17